Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(8):589; doi:10.1093/jnci/djk173
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Savage, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

Breast Cancer Stamp Funds Produce Results

Liz Savage

Funds from the breast cancer stamp are now being used in a different way, but two previous funding efforts had also produced results. The first, the Insight Awards to Stamp Out Breast Cancer, funded high-risk research conducted by investigators outside the federal government. The second, the Exceptional Opportunities in Breast Cancer Research fund, supported established research that hadn’t been funded because of lack of money. Several advances in breast cancer research have come from these grants.

  • Susan Neuhausen, Ph.D., an epidemiologist at the University of California, Irvine, has been awarded several grants to investigate the breast and ovarian cancer risk in women with BRCA1 and -2 mutations. This research has led to new insights into how this risk is affected by pregnancy, hormone replacement therapy, and abortion.
  • A group of Japanese researchers identified peptides found in the blood of cancer patients that bind to ErbB2 and Grb7—genes that are expressed in breast and esophageal cancers. Future research will investigate whether using these peptides as drug targets is possible.
  • A group at the Massachusetts General Hospital center for cancer led by Daniel Haber, M.D., Ph.D., established a national referral center for families with Li-Fraumeni syndrome, a rare hereditary genetic disorder that is responsible for the development of multiple cancers, including breast cancer, often at an early age. Haber and his team developed new methods for detecting mutations to p53, which cause the syndrome. Doing so allowed them to identify more families and collect more genetic material, which they can use to find the genetic mutations that lead to LFS and other multicancer syndromes.
  • Other advances include the development of several therapeutic and chemoprevention treatments that show promise for fighting breast cancer in animal models; the creation of a test that detects the absence of a tumor suppressor gene, which could better predict breast cancer prognosis; and new techniques for imaging spontaneous breast cancer in mice.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Savage, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?